SiranBio was established in May 2022 in Suzhou Industrial Park. We are a bio✔tech company specialized in siRNA drug development. Our core team is consisted of top sσcientists and pioneers of siRNA drugs in China. Several preσstigious awards has been given to our company since its inception, such as The Leading Enterpris∏e in Suzhou Industrial Park and as Gusu Leading Enterp​rise in 2002.

We have developed comprehensive and proprietary platform εtechnologies which encompass the whole process of siRNA drug development, including siRNA s✘equence design and screening, chemical modifications for PD enhancement and off-target attenuation> (eSAFE), liver and extrahepatic delivery (STORK), and dual-targeting siRNA. Based o↔n these innovative technologies, we very quickly established a robust pipeline with♣ potentials to become First-in-Class (FIC) and Best-in-Class (BIC) siRNA the♥rapeutics for several important therapeutic areas, including anti-viral, cardiovascular and♣ metabolic diseases, autoimmune diseases, CNS diseases.

We always put the patients’ needs in the highest priority, to innovate best ©siRNA drugs for the health and well-being of human kind.